BUFFALO, NYRoswell Park Cancer Institute is offering a new
blood test to detect early prostate cancer. The complexed
prostate-specific antigen (cPSA) test appears to be more accurate
than standard PSA at differentiating between prostate cancer and
benign conditions, and thus may eliminate the need for unnecessary
biopsies when PSA tests are ambiguous.
The cPSA test measures levels of PSA complexed with
alpha-1-antichymotrypsin, which makes up the bulk of circulating PSA
in men with prostate cancer.
Currently, the cPSA test is only being offered as a follow-up
procedure for men whose original PSA test didnt clearly
identify the need for a biopsy, said John S.J. Brooks, MD,
chairman of the Division of Pathology & Laboratory Medicine at
Roswell Park. When a standard PSA test is in the ambiguous
range of 4 to 10 ng/mL, the decision to biopsy a patient is unclear.
A positive cPSA test suggests a greater chance of prostate cancer. A
negative cPSA test would eliminate unnecessary biopsies.
Roswell Park is participating in a collaborative study to help
determine if the cPSA blood test should replace the standard PSA
blood test in general prostate cancer screening programs. For more
information about this test and other prostate cancer screening
programs, call 1-800-ROSWELL (1-800-767-9355).